| CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase K Krysiak, AM Danos, J Saliba, JF McMichael, AC Coffman, S Kiwala, ... Nucleic Acids Research 51 (D1), D1230-D1241, 2023 | 12 | 2023 |
| A community approach to the cancer-variant-interpretation bottleneck K Krysiak, AM Danos, S Kiwala, JF McMichael, AC Coffman, EK Barnell, ... Nature Cancer 3 (5), 522-525, 2022 | 3 | 2022 |
| The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute … A Marr, S Karmahapatra, D Corbin, Y Asemelash, S Sher, SR Mitchell, ... Blood 140 (Supplement 1), 3075-3076, 2022 | 1 | 2022 |
| The multi-CDK inhibitor dinaciclib reverses bromo-and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling AR Marr, M Halpin, DL Corbin, Y Asemelash, S Sher, BK Gordon, ... Experimental Hematology & Oncology 13 (1), 27, 2024 | | 2024 |
| Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168 B Gordon, E Muhowski, J Ravikrishnan, S Benrashid, A Mitchell, A He, ... Blood 142, 416, 2023 | | 2023 |
| The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia B Gordon, E Muhowski, J Ravikrishnan, S Thangavadivel, S Benrashid, ... Blood 142, 2260, 2023 | | 2023 |
| Brd4 Inhibition Abrogates Inflammation and Self-Renewal in a Murine Model of Tet2 Mutated Clonal Hematopoiesis A Marr, M Halpin, D Corbin, B Gordon, S Benrashid, EC Whipp, ... Blood 142, 4070, 2023 | | 2023 |
| Development of Evidence Statement curation algorithms to aid cancer variant interpretation J Saliba, L Sheta, K Krysiak, A Danos, A Marr, E Barnell, S Pema, WH Lin, ... Cancer Research 81 (13_Supplement), 208-208, 2021 | | 2021 |
